4th Quarter - Report

NATIONAL VENTURE CAPITAL ASSOCIATION for NATIONAL VENTURE CAPITAL ASSOCIATION

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$514,107
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report (this page) Jan 16, 2014 $514,107 Replaced
4th Quarter - Amendment Jul 6, 2016 $514,107 Yes

What was lobbied

8 issue areas, each in the filer's own words, with who lobbied on it and where.

Banking BAN

Implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (PL 111-203) Implementation of the JOBS Act Review of decimalization study by the SEC, required under the JOBS Act

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN —
MARK HEESEN —
KELLY SLONE —

Contacted: Securities & Exchange Commission (SEC); HOUSE OF REPRESENTATIVES; Treasury, Dept of; SENATE; White House Office; Food & Drug Administration (FDA)

Telecommunications TEC

HR 1468 Secure IT Act: Bills to protect critical infrastructure against cyber based espionage, IP theft and terror attacks; Privacy and Information Sharing issues; S.21 Cybersecurity and American Cyber Competitiveness Act of 2013; HR 624 Cyber Intelligence Sharing and Protection Act (CISPA)

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN —
MARK HEESEN —
KELLY SLONE —

Contacted: Securities & Exchange Commission (SEC); HOUSE OF REPRESENTATIVES; Treasury, Dept of; White House Office; SENATE; Food & Drug Administration (FDA)

Bills named: S. 21 (113th), H.R. 624 (113th), H.R. 1468 (113th)

Health Issues HCR

No bill #: Lobbied Congress to work the FDA to create a new approval pathway that could help expedite the development of certain drugs that address unmet medical needs, referred to as a special medical use pathway which can be used for a broad set of discussions No bill #: Lobbied Congress on the need for a transparent regulatory pathway for market-based reimbursement for advanced diagnostics. FDA Medical Mobile apps

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN —
MARK HEESEN —
KELLY SLONE —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; White House Office; SENATE; Securities & Exchange Commission (SEC); Treasury, Dept of

Energy/Nuclear ENG

Cleantech and Energy Policy Issues. New Energy Innovation Tax issues; ARPA-E Funding; HR 2609 FY 2014 Energy and Water Appropriations. Senate Finance Energy Tax Paper

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN —
MARK HEESEN —
KELLY SLONE —

Contacted: Securities & Exchange Commission (SEC); Food & Drug Administration (FDA); White House Office; Treasury, Dept of; HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2609 (113th)

Immigration IMM

Support for S.310, Startup Act 3.0; S.169 Immigration Innovation Act of 2013; S.189 Startup VISA Act of 2013; Gang of 8 Bipartisan Framework for Comprehensive Immigration Reform; Invest VISA, Entrepreneurial VISA, HR 2131 S744 Border Security, Economic Opportunity and Immigration Modernization Act

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN —
MARK HEESEN —
KELLY SLONE —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Securities & Exchange Commission (SEC); Treasury, Dept of; White House Office

Bills named: S. 310 (113th), H.R. 2131 (113th), S. 189 (113th), S. 169 (113th)

Taxation/Internal Revenue Code TAX

S.232/HR 1295 Medical Device Access and Innovation Protection Act: would appeal the medical device tax as part of the ACA; S. Con Resolution 8: an original resolution setting forth the Congressional Budget for FY2014 which would repeal the medical device tax but not identify a pay for: HR 523 Protect the Medical Innovation Act of 2013

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN —
MARK HEESEN —
KELLY SLONE —

Contacted: Treasury, Dept of; Food & Drug Administration (FDA); White House Office; HOUSE OF REPRESENTATIVES; SENATE; Securities & Exchange Commission (SEC)

Bills named: S. 232 (113th), H.R. 523 (113th), H.R. 1295 (113th)

Copyright/Patent/Trademark CPT

HR 3309, S.1720, S.1612, S.1013, 5.806 -- various patent reform bills

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN —
MARK HEESEN —
KELLY SLONE —

Contacted: Treasury, Dept of; White House Office; SENATE; Securities & Exchange Commission (SEC); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: S. 1013 (113th), S. 1720 (113th), H.R. 3309 (113th), S. 1612 (113th)

Science/Technology SCI

Basic science research funding HR 2981 Technology and Research National Security and Future Economic Resiliency Act (TRANSFER Act)

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN —
MARK HEESEN —
KELLY SLONE —

Contacted: White House Office; Treasury, Dept of; SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Securities & Exchange Commission (SEC)

Bills named: H.R. 2981 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.